{"id":"NCT00537485","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients","officialTitle":"A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2007-09","primaryCompletion":"2009-12","completion":"2009-12","firstPosted":"2007-10-01","resultsPosted":"2014-03-19","lastUpdate":"2014-03-19"},"enrollment":180,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Early Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"SPM 962","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"To investigate superiority of SPM 962 over placebo in early Parkinson's disease patients in a multi-center, placebo-controlled, double-blind study following once-daily multiple transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg (12-week dose titration/maintenance period)","primaryOutcome":{"measure":"Change From Baseline to the End of Maintenance Period in Total of Each Sum Score of UPDRS Part 2 and Part 3","timeFrame":"baseline, end of maintenance period","effectByArm":[{"arm":"SPM962","deltaMin":-8.4,"sd":9.7},{"arm":"Placebo","deltaMin":-4.1,"sd":8.2}],"pValues":[{"comp":"OG000 vs OG001","p":"0.002"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":90},"commonTop":["Application Site Reaction","Nasopharyngitis","Nausea","Constipation","Somnolence"]}}